CFM
MCRB icon

Catalyst Funds Management’s Seres Therapeutics MCRB Stock Holding History

Catalyst Funds Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,245
Closed -$20.7K – 535
2024
Q4 		$20.7K Hold
1,245
– – 0.01% 292
2024
Q3 		$23.6K Hold
1,245
– – 0.01% 1049
2024
Q2 		$18K Sell
1,245
-3,555
-74% -$59.3K ﹤0.01% 718
2024
Q1 		$74.3K Buy
+4,800
New +$104K 0.02% 470

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Catalyst Funds Management's MCRB Position: Q1 2025 in Review

Catalyst Funds Management sold out of Seres Therapeutics (MCRB) in Q1 2025, closing a stake of 1,245 shares — an estimated $20.7K sold.

Catalyst Funds Management first reported a position in MCRB in Q1 2024 and held it in 4 quarters. The position peaked at $74.3K in Q1 2024. 63 funds tracked by Wall St. Rank hold MCRB as of Q1 2025.

  • Catalyst Funds Management reported no remaining Seres Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Catalyst Funds Management sold 1,245 Seres Therapeutics shares in Q1 2025, an estimated $20.7K.
  • Catalyst Funds Management first reported a position in Seres Therapeutics in Q1 2024 and held it in 4 quarters.
  • Catalyst Funds Management's Seres Therapeutics position peaked at $74.3K in Q1 2024.
  • 63 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2025.

Based on Catalyst Funds Management's 13F filing for Q1 2025, filed 14 May 2025.